Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Adjuvant T-DM1 bij stadium I HER2-positieve borstkanker: resultaten na 5 jaar
nov 2024 | Borstkanker